Symbol="IOVA"
AssetType="Common Stock"
Name="Iovance Biotherapeutics Inc"
Description="Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California."
CIK="1425205"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)"
Address="999 SKYWAY ROAD, SUITE 150, SAN CARLOS, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="1779158000"
EBITDA="-407744000"
PERatio="None"
PEGRatio="0"
BookValue="2.66"
DividendPerShare="0"
DividendYield="0"
EPS="-2.33"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.342"
ReturnOnEquityTTM="-0.675"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-2.33"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="24.55"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="2.774"
EVToRevenue="-"
EVToEBITDA="-2.187"
Beta="0.0942"
num_52WeekHigh="13.32"
num_52WeekLow="5.28"
num_50DayMovingAverage="7.78"
num_200DayMovingAverage="7.17"
SharesOutstanding="247449000"
DividendDate="None"
ExDividendDate="None"
symbol="IOVA"
open="7.58"
high="7.58"
low="7.00"
price="7.19"
volume="5775787.00"
latest_trading_day="2023-08-10"
previous_close="7.60"
change="-0.41"
change_percent="-5.3947%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="37"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="63"
Volume_recent_avg="5195144"
Change_recent_avg="-0.02"
Delta_recent_avg="0.42"
Variance_recent_avg="0.21"
Change_ratio_recent_avg="-0.34"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="63"
Aroon_momentum_negative="37"
image_negative_thumbnail_id_1="161"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0015.jpeg"
image_negative_thumbnail_id_2="1141"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0174.jpeg"
image_neutral_thumbnail_id_1="540"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0059.jpeg"
image_neutral_thumbnail_id_2="598"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_positive_thumbnail_id_1="1015"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0177.jpeg"
image_positive_thumbnail_id_2="704"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0004.jpeg"
image_professor_thumbnail_id_1="1168"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0002.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
